|
|
||||||||
From the Health Investigations Branch, Division of Health Studies, Agency for Toxic Substances and Disease Registry (Drs. Noonan and Wong), the Division of Cancer Prevention and Control (Dr. White), and the Division of Adult and Community Health (Dr. Thurman), National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
Address correspondence and reprint requests to Dr. Curtis W. Noonan, Center for Environmental Health Sciences, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812; e-mail: curtis.noonan{at}umontana.edu
Objective: To describe temporal trends of motor neuron disease (MND) mortality in the United States. Variations in MND by demographic variables of sex, age, geography, and race/ethnicity were evaluated to assess the possible explanations for observed trends.
Methods: Multiple-cause mortality files from the National Center for Health Statistics for the years 1969 through 1998 were searched for all United States death records with codes corresponding to MND. Age-adjusted mortality rates were calculated by sex, race/ethnicity, age, birth cohort, and place of death.
Results: Overall MND mortality rates increased from 1.25 per 100,000 to 1.82 per 100,000, representing a 46% increase during the 30-year period. Rates among women increased by 60% and continue to rise. Rates among men rose by 35% during this period but have leveled off in the most recent decade evaluated. Mortality rates among African Americans and Hispanics were approximately 50% lower than rates among non-Hispanic whites. A southeast to northwest gradient was observed when rates were grouped by 12 geographic areas. MND mortality rates per 100,000 (and 95% CI) ranged from 2.22 (1.89 to 2.55) in the Northwest to 1.57 (1.44 to 1.71) in the Southeast.
Conclusions: Variations in motor neuron disease (MND) mortality by time, race/ethnicity, sex, and geography were consistent with the hypothesis that environmental exposures, combined with factors of genetic susceptibility, play a role in the development of MND.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the April 12 issue to find the title link for this article.
Received June 15, 2004. Accepted in final form December 14, 2004.
This article has been cited by other articles:
![]() |
O O'Toole, B J Traynor, P Brennan, C Sheehan, E Frost, B Corr, and O Hardiman Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004 J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 30 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cronin, O. Hardiman, and B. J. Traynor Ethnic variation in the incidence of ALS: A systematic review Neurology, March 27, 2007; 68(13): 1002 - 1007. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Choudry and M. E. Cudkowicz Clinical Trials in Amyotrophic Lateral Sclerosis: The Tenuous Past and the Promising Future J. Clin. Pharmacol., December 1, 2005; 45(12): 1334 - 1344. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |